Philadelphia Semiconductor Index (SOXX): ALTR - Daily, Weekly, Monthly charts...

Play Episode

5min

Proactive - Interviews for investors

Lithium ION Energy secures joint venture with SureFQ to advance Urgakh Naran Lithium project

Lithium ION Energy Limited CEO Ali Haji joined Steve Darling from Proactive to announce a binding Joint Venture Agreement with SureFQ for the advancement of the Urgakh Naran lithium project in Mongolia. Under the agreement, ION will retain a 20% free carried interest through to commercial production, ensuring long-term participation in the project's success without additional financial commitments. SureFQ, a firm specializing in sustainable energy solutions and lithium resource development, will leverage its industry expertise and advanced extraction technologies to accelerate the project’s progress. As a strategic investor, SureFQ focuses on developing high-potential assets that support the global energy transition. Haji told Proactive SureFQ will provide $5.5 million in cash considerations to ION over 4.5 years. The company has committed to $8 million in development expenditures for Urgakh Naran over four years. ION Energy will maintain a 2.5% Net Smelter Return (NSR) royalty in perpetuity, ensuring a steady revenue stream from future production. Haji emphasized that ION Energy is a proven Direct Lithium Extraction (DLE) operator, focused on deploying modular extraction capacity to optimize efficiency. This partnership positions Urgakh Naran as a key lithium asset in Mongolia, furthering ION’s role in the global battery metals supply chain. #proactiveinvestors #lithiumionenergylimited #tsxv #ion #urgakhnaran #mongolia #lithium #IonEnergy #AliHaji #UrgakhNaran #SureFQ #MongoliaMining #LithiumExtraction #DLETechnology #BatteryMetals #EVSupplyChain #CriticalMinerals #MiningInvestment #ProactiveInvestors #JuniorMining

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Proactive - Interviews for investors

Caledonia Mining sees big profit jump in 2024; welcomes gold's move above $3,000

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth talked with Proactive's Stephen Gunnion about the company’s strong 2024 financial performance and strategic priorities following the release of its latest results. Learmonth reported a “strong end to a reasonably good year,” with annual gold production reaching approximately 78,000 ounces—within guidance—supported by favourable pricing. He highlighted that “gross profit for the year was 77 million, compared to 41 million last year,” with adjusted earnings per share rising sharply from less than $0.10 in 2023 to nearly $1.30 in 2024. The results were delayed due to a technical accounting issue, with Learmonth explaining this stemmed from a deferred tax calculation error dating back to 2019. He stressed it had “no impact on our actual tax liabilities and tax payments.” On project development, the feasibility study for the Bilboes project has been extended to evaluate options that could significantly reduce capital costs. These include the potential to export concentrate and relocate the tailings facility, potentially lowering upfront investment needs. Exploration at both Blanket and Motapa returned positive results. Learmonth noted that the Blanket resource base has been extended, and early work at Motapa uncovered “exciting mineralisation” in new areas. With gold prices currently above $3,000 per ounce, the company is focused on maximising cash flow and investing further in Blanket and other revenue-generating opportunities. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future content. #CaledoniaMining #GoldMining #MarkLearmonth #MiningStocks #GoldPrice #ZimbabweMining #BilboesProject #BlanketMine #MotapaExploration #InvestingInMining #MiningUpdate #ProactiveInvestors

Proactive - Interviews for investors

OKYO Pharma achieves key stability milestone for Urcosimod in clinical development

OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share a significant advancement in the company’s ongoing drug development efforts. The company has successfully demonstrated that urcosimod—formerly known as OK-101—remains stable for more than two and a half years in single-use ampoules, which are used for patient administration. This milestone is a crucial step forward in ensuring the long-term viability of the drug as it progresses through clinical trials. Urcosimod is currently being evaluated in a Phase 2b clinical trial, which is a randomized, placebo-controlled, double-masked study involving 48 patients. The trial is focused on assessing the drug’s effectiveness in treating neurotrophic keratopathy (NCP), a serious and progressive degenerative eye disease. Jacob emphasized that achieving success in clinical development extends beyond obtaining positive clinical trial data. A crucial aspect of regulatory approval includes meeting the rigorous Chemistry, Manufacturing, and Controls (CMC) requirements set by the U.S. Food and Drug Administration (FDA). By demonstrating long-term stability, OKYO Pharma has strengthened its regulatory submission package, addressing an essential factor in the drug’s future approval and commercialization. The company recently completed Good Manufacturing Practice (GMP) stability assay testing of single-use ampoules containing urcosimod in an ophthalmic solution. The results were highly promising—ampoules stored under refrigerated conditions maintained stability for over two and a half years, while initial three-month data from samples stored at room temperature showed potency levels at or above 100%. These findings reinforce confidence in urcosimod’s shelf life and its potential for real-world clinical use. As OKYO Pharma continues to advance urcosimod through the regulatory and clinical development process, this stability milestone represents a critical achievement in its journey toward providing an effective tr

Followers	213
Posts	73537
Boards Moderated	0
Alias Born	03/01/2004

Volume:	13,853,836
Day Range:	154.61 - 165.765
Bid:	156.60
Ask:	156.80
Last Trade Time:	4:37:00 PM EDT
Total Trades:	182,779

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

SOXX Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free